UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.

About three million Americans take antipsychotic medications for conditions such as bipolar disorder, PTSD and schizophrenia. These medications are vital for mental health, yet many people stop taking them because of the side effects of weight gain and associated metabolic diseases.

Chronic cellular stress mechanisms have been linked to the poor development of insulin-producing cells, in a study using gene-edited stem cells.

This article discusses the relationship between cell signaling and cancer, highlights key signaling pathways involved in cancer, and explores how critical mediators of aberrant signaling can be turned into therapeutic targets for cancer.

This article highlights the properties of an attractive drug target, outlines the approaches used to identify targets, and discusses the key steps involved in target validation and the benefits and challenges of using siRNA to validate targets.

A video showing the birth of an incredible network of neurons in the nervous system of a Zebrafish has won first prize at the Nikon Small World in Motion Awards, which highlight the best in photography and video captured through the microscope lens. We caught up with researchers behind the video to find out more.

Scientists have discovered powerful new reactions for the synthesis of nature-inspired privileged structures – one-pot, modular, elegantly designed chemical reactions that could minimize the gap between the chemical and biological space. Their study findings could be a turning point for the discovery of unmet diseases.

Although many new cellular assays entered the drug discovery scene over the course of the last decades, we still lack a predictable tool when it comes to selecting compounds or cell lines for xenograft testing. What is lacking?

We are entering uncharted territory in biopharmaceutical development. Emerging new classes of treatments are harnessing the natural power of viruses and cells and engineering them to fight human diseases. As our arsenal of conventional therapies begins to fail, a new army of biotherapeutics is on the horizon. Here, we look at two new classes of treatments leading the charge.